Renaissance Technologies’s Heron Therapeutics HRTX Stock Holding History

Renaissance Technologies’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$643K	Sell	1,506,900 -211,400	-12%	-$170K	﹤0.01%	2504
2026 Q1	$1.37M	Sell	1,718,300 -197,600	-10%	-$229K	﹤0.01%	2104
2025 Q4	$2.49M	Sell	1,915,900 -939,099	-33%	-$1.16M	﹤0.01%	1730
2025 Q3	$3.6M	Buy	2,854,999 +165,660	+6%	+$263K	﹤0.01%	1677
2025 Q2	$5.57M	Buy	2,689,339 +414,839	+18%	+$847K	0.01%	1458
2025 Q1	$5M	Buy	2,274,500 +1,085,700	+91%	+$2.11M	0.01%	1427
2024 Q4	$1.82M	Sell	1,188,800 -819,398	-41%	-$1.33M	﹤0.01%	2120
2024 Q3	$4M	Buy	2,008,198 +14,398	+0.7%	+$34.4K	0.01%	1587
2024 Q2	$6.98M	Sell	1,993,800 -412,686	-17%	-$1.27M	0.01%	1114
2024 Q1	$6.67M	Buy	2,406,486 +523,186	+28%	+$1.32M	0.01%	1233
2023 Q4	$3.2M	Buy	1,883,300 +1,592,000	+547%	+$1.75M	0.01%	1641
2023 Q3	$300K	Sell	291,300 -767,800	-72%	-$1.09M	﹤0.01%	2933
2023 Q2	$1.23M	Sell	1,059,100 -81,736	-7%	-$146K	﹤0.01%	2338
2023 Q1	$1.72M	Buy	1,140,836 +814,336	+249%	+$2.04M	﹤0.01%	2122
2022 Q4	$816K	Buy	+326,500	New	+$1.05M	﹤0.01%	2656
2021 Q2	–	Sell	-162,600	Closed	-$2.64M	–	3600
2021 Q1	$2.64M	Buy	+162,600	New	+$2.9M	﹤0.01%	2041
2020 Q4	–	Sell	-134,800	Closed	-$2M	–	3519
2020 Q3	$2M	Sell	134,800 -105,000	-44%	-$1.64M	﹤0.01%	2136
2020 Q2	$3.53M	Sell	239,800 -812,092	-77%	-$13.3M	﹤0.01%	1845
2020 Q1	$12.3M	Buy	1,051,892 +870,892	+481%	+$16.4M	0.01%	1033
2019 Q4	$4.25M	Buy	+181,000	New	+$4M	﹤0.01%	1956
2019 Q3	–	Sell	-97,400	Closed	-$1.81M	–	3538
2019 Q2	$1.81M	Buy	+97,400	New	+$1.95M	﹤0.01%	2380
2018 Q4	–	Sell	-134,100	Closed	-$4.24M	–	3464
2018 Q3	$4.24M	Sell	134,100 -258,400	-66%	-$9.62M	﹤0.01%	1910
2018 Q2	$15.2M	Buy	+392,500	New	+$12.5M	0.02%	1101
2018 Q1	–	Sell	-79,800	Closed	-$1.44M	–	3446
2017 Q4	$1.44M	Buy	+79,800	New	+$1.3M	﹤0.01%	2508
2015 Q3	–	Sell	-48,100	Closed	-$1.5M	–	3245
2015 Q2	$1.5M	Buy	+48,100	New	+$905K	﹤0.01%	2238

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Renaissance Technologies's HRTX Position: Q2 2026 in Review

Renaissance Technologies reduced its Heron Therapeutics (HRTX) stake by 12% in Q2 2026, selling an estimated $170K and leaving 1,506,900 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

Renaissance Technologies first reported a position in HRTX in Q2 2015 and has held it in 25 quarters since. The position peaked at $15.2M in Q2 2018. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Renaissance Technologies held 1,506,900 shares of Heron Therapeutics worth $643K as of Q2 2026.
Renaissance Technologies sold 211,400 Heron Therapeutics shares in Q2 2026, an estimated $170K.
Heron Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2504 holding.
Renaissance Technologies first reported a position in Heron Therapeutics in Q2 2015 and has held it in 25 quarters since.
Renaissance Technologies's Heron Therapeutics position peaked at $15.2M in Q2 2018.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.